AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
_6ff029a61766633234293.png?format=webp&width=1186&height=250)
Os Therapies Incorporated shares rise 1.14% intraday after Lantern Pharma's subsidiary cleared IND application for GBM trial.
ByAinvest
Friday, Aug 8, 2025 9:32 am ET1min read
Os Therapies Incorporated rose 1.14% in intraday trading, with recent news events including Lantern Pharma's subsidiary, Starlight Therapeutics, receiving FDA clearance for a Phase Ib/2a clinical trial to evaluate STAR-001 in combination with spironolactone for patients with glioblastoma multiforme (GBM) at first progression. Additionally, Cytokinetics reported progress in regulatory reviews of Aficamten for obstructive HCM, with a late-cycle meeting with the U.S. FDA scheduled for September ahead of the December 26, 2025 PDUFA date. Genmab also reported positive developments, including the advancement of epcoritamab to earlier lines of therapy and encouraging antitumor activity in endometrial cancer for Rinatabart sesutecan.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet